

Paper # 41  
Attic

FORM PTO-1449 (Modified)  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Attorney Docket No.: 11823-002630US	Application No.: 08/484,537			
		Applicant: QUEEN ET AL.				
		Filing Date: June 7, 1995	Group: 1642			
Reference Designation		U.S. PATENT DOCUMENTS			Page 1 of 2	
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
AB	Opposition to EP 0456216, Third Party Observations, May 25, 1998.					
AB	Opposition to EP 0456216, Further Submissions of Medical Research Council, June 24, 1998.					
AC	Opposition to EP 0456216, Summons to Attend Oral Proceedings, May 12, 1999.					
AD	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., September 17, 1999.					
AE	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., October 26, 1999.					
AF	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., December 1, 1999.					
AG	Opposition to EP 0456216, Further Third Party Observations, December 14, 1999.					
AH	Opposition to EP 0456216, Further Submissions of Celltech Therapeutics, December 16, 1999.					
AI	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Declaration of Thornton/Martin.					
AJ	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: printouts from Protein Design Labs, Inc.'s website.					
AK	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Tables showing derivatization of the antibody domains referred to in Fig. 3 / line 4 and Fig. 4F of WO 88/09344.					
AL	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Schomburg, in <i>Advances in Protein Design</i> , Blöcker et al. (Eds.), 1989, pp. 45-56.					
AM	Opposition to EP 0456216, Further Submissions of Genentech, Inc., December 17, 1999.					
AN	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Verhoeven (including exhibits A, B and C).					
AO	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Shak (including exhibits A, B and C).					
AP	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Presta (including exhibits A and B).					
AQ	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Reply of Protein Design Labs, Inc. in European patent application 92903551.7.					
AR	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Letter of Dr. Seemann.					
AS	Opposition to EP 0456216, Observations of Protein Design Labs, Inc., December 17, 1999.					
AT	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of F. Vincenti (including exhibits 1 and 2).					
AU	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of D. A. Scheinberg (including exhibits 1-4).					
EXAMINER	Celia Burke, RLD		DATE CONSIDERED	4/28/00		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Paper #41  
Paper #41  
Attachment

FORM PTO-1449 (Modified)	Attorney Docket No.: 11823-002630US	Application No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: QUEEN ET AL.	
	Filing Date: June 7, 1995	Group: 1642

**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

Page 2 of 2

QB AV	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Sung Co and Experimental report.
AW	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of C. Nan Chang and Experimental report.
AX	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. D. Kornberg.
AY	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Levitt.
AZ	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of A. B. Edmundson.
BA	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. Kirkman.
BB	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. Junghans (including exhibits 1-6).
BC	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Vasquez.
BE D	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of D. Panka.
BF E	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. J. Poljak.
BG F	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of J. S. Huston.
BN G	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of C. Queen and experimental report.
BN H	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of N. Tsurushita and experimental report.
BN I	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of W. Smith.
BN J	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Examiner's Reasons for Allowance for U.S. Patent No. 5,225,539.
BL K	Opposition to EP 0456216, Further Submissions of Schering Corp., February 11, 2000.
BM L	Opposition to EP 0456216, Further Submissions of Genentech, Inc., March 8, 2000.
BN M	Opposition to EP 0456216, Attachment to Genentech's submissions of March 8, 2000: Declaration of Foote.
BO N	Opposition to EP 0456216, Further Submissions of Genentech, Inc., March 13, 2000.
BP O	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., March 16, 2000.
QB P	Opposition to EP 0456216, Minutes of Oral Proceedings issued by the EPO, April 5, 2000.

EXAMINER

Julie Burke, TLD

DATE CONSIDERED

4/28/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

Attorney Docket No.  
011823-002630Serial No.:  
08/484,537LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT  
(Use several sheets if necessary)

Applicant: Queen

Filing Date: 6/7/95

Group: 1806

D33	<del>Winter patent (Medical Research Council) See AV</del>	See Foreign Patent Documents
D34	<del>Diamanstein application (Bayer Aktiengesellschaft) See AW</del>	.. .. .. .. ..
D35	<del>Verhoeven, BioEssays 8 (February/March 1988), 74-78</del>	
D36	<del>QR Riechmann, Nature 332 (March 1988), 323-327</del>	
D37	<del>QR Verhoeven, Science 239 (March 1988), 1534-1536</del>	
D38	<del>QR Panka, Proc. Natl. Acad. Sci. USA 85 (May 1988) 3080-3084</del>	
D39	<del>QR Davies, J. Biol. Chem., 263 (1988), 10541-10544</del>	
D40	<del>QR Cheetham, Prot. Eng., 2 (September 1988) 170-172</del>	
D41	<del>QR Matsumura, Nature, 334 (1988), 406-410</del>	
D42	<del>Huston application (Creative Biomolecules) See AX</del>	See Foreign Patent Documents
D42'	<del>Huston (Creative Biomolecules) WO88/09344 (December 1, 1988), Fig. 3 .. .. ..</del>	
D43	<del>Huston application, See AX</del>	See Foreign Patent Documents
D44	<del>Comparison Chart for EP-A1 0 318 554 (Huston) .. .. ..</del>	
D45	<del>QR Hale, The Lancet 2 (December 17, 1988), 1394-1399</del>	
D46	<del>Bodmer application, (Celltech Limited), See AZ</del>	See Foreign Patent Documents
D47	<del>Hardman application, (Ciba-Geigy AG), See A1</del>	
D48	<del>Clark application (Medical Research Council), See A2</del>	
D49	<del>Queen application (Protein Design Labs, See A3</del>	
D50	<del>Hinton application (Becton Dickinson), See A4</del>	
D51	<del>Mezes application, (Dow Chemical) See A5</del>	↓
D52	<del>QR Queen, Proc. Natl. Acad. Sci., USA 86 (December 1989), 10029-10033</del>	
D53	<del>QR Chothia, Nature, 342, (1989), 877-883</del>	
D54	<del>QR Tramontano, J. Mol. Biol., 215 (1990), 175-182</del>	
D55	<del>Queen Application (Protein Design Labs) See AA</del>	See US Patent Documents
D56	<del>QR Co, Proc. Natl. Acad. Sci., USA 88 (1991), 2869-2873</del>	
D57	<del>QR Gorman, Proc. Natl. Acad. Sci., USA, 88 (1991), 4181-4185</del>	
D58	<del>QR Routledge, Eur. J. Immunol., 21 (1991), 2717-2725</del>	
D59	<del>QR Shearman, J. Immunol., 147 (1991), 4366-4373</del>	
D60	<del>QR Kettleborough, Protein Engineering, 4, (1991), 773-783</del>	
D61	<del>QR Tempest, Bio/Technology, 9, (1991), 266-271</del>	

Julie (Reeves, PL)

B Jr 99